Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Cell Therapy Transplant Canada.

Lancet Haematol. 2020 Feb;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0. Epub 2020 Jan 17. Erratum in: Lancet Haematol. 2020 Jan 29;:.

PMID:
31958417
2.

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.

Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Larochelle F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagacé M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G.

Lancet Haematol. 2020 Feb;7(2):e134-e145. doi: 10.1016/S2352-3026(19)30202-9. Epub 2019 Nov 6.

PMID:
31704264
3.

Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.

Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S.

Biol Blood Marrow Transplant. 2020 Jan;26(1):157-161. doi: 10.1016/j.bbmt.2019.09.007. Epub 2019 Sep 12.

PMID:
31521818
4.

Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.

Roy DC, Lachance S, Cohen S, Delisle JS, Kiss T, Sauvageau G, Busque L, Ahmad I, Bernard L, Bambace N, Boumédine RS, Guertin MC, Rezvani K, Mielke S, Perreault C, Roy J.

Br J Haematol. 2019 Sep;186(5):754-766. doi: 10.1111/bjh.15970. Epub 2019 May 28.

5.

Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.

Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S.

Leuk Res. 2019 Apr;79:75-80. doi: 10.1016/j.leukres.2019.01.002. Epub 2019 Jan 6.

PMID:
30654975
6.

Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity.

Hillhouse EE, Thiant S, Moutuou MM, Lombard-Vadnais F, Parat R, Delisle JS, Ahmad I, Roy DC, Guimond M, Roy J, Lesage S.

Biol Blood Marrow Transplant. 2019 Jan;25(1):19-25. doi: 10.1016/j.bbmt.2018.09.008. Epub 2018 Sep 19.

7.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Canadian Blood and Marrow Transplant Group.

Lancet Oncol. 2016 Feb;17(2):164-173. doi: 10.1016/S1470-2045(15)00462-3. Epub 2015 Dec 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
26723083
8.

A systematic review of risk factors associated with the introduction of Mycobacterium avium spp. paratuberculosis (MAP) into dairy herds.

Rangel SJ, Paré J, Doré E, Arango JC, Côté G, Buczinski S, Labrecque O, Fairbrother JH, Roy JP, Wellemans V, Fecteau G.

Can Vet J. 2015 Feb;56(2):169-77. Review.

9.

Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.

Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA.

Br J Haematol. 2015 Feb;168(4):511-7. doi: 10.1111/bjh.13176. Epub 2014 Oct 10.

PMID:
25302852
10.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

11.

Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.

Holbro A, Ahmad I, Cohen S, Roy J, Lachance S, Chagnon M, LeBlanc R, Bernard L, Busque L, Roy DC, Sauvageau G, Kiss TL.

Biol Blood Marrow Transplant. 2013 Apr;19(4):547-51. doi: 10.1016/j.bbmt.2012.12.006. Epub 2012 Dec 16.

12.

Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.

Bastien JP, Roy J, Roy DC.

Semin Oncol. 2012 Dec;39(6):674-82. doi: 10.1053/j.seminoncol.2012.09.004. Review.

PMID:
23206844
13.

Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment.

Abouelnasr A, Roy J, Cohen S, Kiss T, Lachance S.

Biol Blood Marrow Transplant. 2013 Jan;19(1):12-21. doi: 10.1016/j.bbmt.2012.06.020. Epub 2012 Jul 5. Review.

14.

Novel, cyclic heat dissipation method for the correction of natural temperature gradients in sap flow measurements. Part 1. Theory and application.

Lubczynski MW, Chavarro-Rincon D, Roy J.

Tree Physiol. 2012 Jul;32(7):894-912. doi: 10.1093/treephys/tps030. Epub 2012 May 18.

PMID:
22611074
15.

Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.

Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L, Ahmad I, Roy J.

Biol Blood Marrow Transplant. 2012 Jun;18(6):951-7. doi: 10.1016/j.bbmt.2011.11.028. Epub 2011 Dec 7.

16.

Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.

Ahmad I, Labbé AC, Chagnon M, Busque L, Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1673-8. doi: 10.1016/j.bbmt.2011.04.012. Epub 2011 May 3.

17.

High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Su SH, Martel-Laferrière V, Labbé AC, Snydman DR, Kent D, Laverdière M, Béliveau C, Logvinenko T, Cohen S, Lachance S, Kiss T, Roy J.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1012-7. doi: 10.1016/j.bbmt.2010.10.025. Epub 2010 Oct 25.

18.

Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies.

Luong ML, Filion C, Labbé AC, Roy J, Pépin J, Cadrin-Tourigny J, Carignan S, Sheppard DC, Laverdière M.

Diagn Microbiol Infect Dis. 2010 Oct;68(2):132-9. doi: 10.1016/j.diagmicrobio.2010.03.017.

PMID:
20846585
19.

NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease.

Boutin M, Ahmad I, Jauhiainen M, Lachapelle N, Rondeau C, Roy J, Thibault P.

Anal Chem. 2009 Nov 15;81(22):9454-61. doi: 10.1021/ac9018796.

PMID:
19848412
20.

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10.

Supplemental Content

Loading ...
Support Center